The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
|Videos|May 28, 2013
The 340B Drug Discount Program
Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
Advertisement
In this video, Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
For more information about Dr. Fein's controversial op-ed on 340B pricing, see
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5